_(52748025943).png)
_(cropped)-(1).jpg)
AstraZeneca inks deal with Alteogen for subcutaneous cancer drugs
AstraZeneca is betting roughly $1.35 billion on Korean biotech Alteogen to help develop under-the-skin versions of multiple oncology therapies. The British pharma will license ALT-B4, a compound that uses a specific enzyme to more efficiently ...
AstraZeneca is betting roughly $1.35 billion on Korean biotech Alteogen to help develop under-the-skin versions of multiple oncology therapies.
The British pharma will license ALT-B4, a compound that uses a specific enzyme to more efficiently ...
